Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M

STANDARD BIOTOOLS INC.

2024-FY EPS reported -$0.52 revenue$174,432,000

Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).
Q4 net loss $34.1M improved from $55.3M loss; adjusted EBITDA loss $18.4M (34% improvement).
Achieved $90M in operational cost synergies, exceeding original target by $10M; cash $295M, no debt.
2025 revenue guidance $165M-$175M, citing anticipated NIH funding pressure and no tariff impact.
Full year consumables revenue up 18% YoY; instruments down 27%; services down 17%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.